Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on shared a post on X:
“Prospective analysis of ctDNA in patients with stage III NSCLC treated with chemoradiation and durvalumab on JTO and JTO CRR. ctDNA detected in 35% after CRT but not prognostic. If ctDNA+ at 6m (in 28%), mPFS 14.7m versus 46.9m if negative (HR 2.45).”
Title: ctDNA based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumab
Authors: Henrik Horndalsveen, Vilde Drageset Haakensen, Tesfaye Madebo, Bjørn Henning Grønberg, Tarje Onsøien Halvorsen, Maria Moksnes Bjaanæs, Britina Kjuul Danielsen, Mari Børve, Solveig Kokkvoll, Tonje Sofie Dalen Boda, Åsa Kristina Öjlert, Åslaug Helland
Other articles featuring Dr. Liu on OncoDaily.